Thiocarbazides Or Thiosemicarbazides (i.e., N-n-c(=s)-n Containing) Patents (Class 514/581)
  • Publication number: 20140371291
    Abstract: A novel serine racemase inhibitor exhibits sufficient activity and specificity. The serine racemase inhibitor includes one or more compounds selected from compounds respectively represented by the following general formulas [MM_1], [DR_1], [DR?_1], [LW_1], and [ED_1] as an active ingredient.
    Type: Application
    Filed: January 24, 2013
    Publication date: December 18, 2014
    Inventors: Hisashi Mori, Naoki Toyooka, Mineyuki Mizuguchi, Takayuki Obita, Syuichi Hirono, Hiroaki Goda
  • Patent number: 8501811
    Abstract: Provided herein are small molecule inhibitors of Taspase1 and methods of using the small molecule inhibitors of Taspase1 to treat neoplasm in subjects in need thereof.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: August 6, 2013
    Assignee: Washington University
    Inventors: James Hsieh, Emily Cheng
  • Publication number: 20120015990
    Abstract: Provided herein are small molecule inhibitors of Taspase1 and methods of using the small molecule inhibitors of Taspase1 to treat neoplasm in subjects in need thereof.
    Type: Application
    Filed: June 17, 2011
    Publication date: January 19, 2012
    Applicant: THE WASHINGTON UNIVERSITY
    Inventors: James Hsieh, Emily Cheng
  • Publication number: 20110118338
    Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.
    Type: Application
    Filed: February 1, 2011
    Publication date: May 19, 2011
    Applicant: GALAPAGOS BV
    Inventors: Reginald Brys, Nick Vandeghinste, Peter Herwig Maria Tomme
  • Publication number: 20110053880
    Abstract: The invention relates to a pharmaceutical composition comprising a compound preventing EthR from binding to the ethA promoter, for example a compound of formula 1 wherein R1 is optionally substituted phenyl or optionally substituted pyridyl; R2 (CH2)n wherein n is 1, 2, 3 or 4; R3 is CH3(CH2)m wherein m is 0, 1, 2 or 3; X1 is O, S, NH, N(CH3) or CH2; and X2 is O, S or NH; in particular 2-phenylethyl butyrate, and a thioamide or thiourea of formula 2 wherein R4 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, —NR7R8; or —NH—N?CH—R9; and substituents R5 to R9 have the meanings indicated in the description, in particular ethionamide. The pharmaceutical composition is useful, e.g., in the treatment of multidrug-resistant tuberculosis.
    Type: Application
    Filed: November 25, 2008
    Publication date: March 3, 2011
    Inventors: Martin Fussenegger, Wilfried Weber, Ronald Schoenmakers
  • Patent number: 7893108
    Abstract: Disclosed herein are antiviral compounds, such as anti-human cytomegalovirus antiviral compounds, pharmaceutical compositions and antiviral methods.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: February 22, 2011
    Assignee: President and Fellows of Harvard College
    Inventors: Donald M. Coen, Arianna Loregian
  • Publication number: 20100316655
    Abstract: Disclosed herein are drug compounds that have MDR-inverse activity and thus are effective against multidrug-resistant cells. Exemplary compounds disclosed herein have the structure: Examples of the disclosed compounds have been found to have, inter alia, efficacy in directly treating multidrug resistant cells, rendering multidrug resistant cells susceptible to other chemotherapeutics and in some instances reversing multidrug resistance.
    Type: Application
    Filed: February 10, 2009
    Publication date: December 16, 2010
    Inventors: Matthew D. Hall, Michael M. Gottesman, Jennifer L. Hellawell, Joseph A. Ludwig, Henry M. Fales, Noeris K. Salam, Gergely Szakács
  • Patent number: 7842728
    Abstract: The present invention provides a synergistic insecticidal composition comprising as essential active ingredients a neuronal sodium channel antagonist in combination with one or more compounds selected from the group consisting of pyrethroids, pyrethroid-type compounds, recombinant nucleopolyhedroviruses capable of expressing an insect toxin, organophosphates, carbamates, formamidines, macrocyclic lactones, amidinohydrazones, GABA antagonists and acetylcholine receptor ligands. Also provided are methods for synergistic insect control and crop protection.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 30, 2010
    Assignee: BASF Aktiengesellschaft
    Inventors: Michael Frank Treacy, Raymond Frank Borysewicz, Kurt Allen Schwinghammer, Paul E. Rensner, Hassan Oloumi-Sadeghi
  • Publication number: 20100298340
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: April 12, 2007
    Publication date: November 25, 2010
    Applicants: AstraZeneca AB, Astex Therapeutics Ltd.
    Inventors: Stefan Berg, Karin Kolmodin
  • Patent number: 7838559
    Abstract: The present invention provides a synergistic insecticidal composition comprising as essential active ingredients a neuronal sodium channel antagonist in combination with one or more compounds selected from the group consisting of pyrethroids, pyrethroid-type compounds, recombinant nucleopolyhedroviruses capable of expressing an insect toxin, organophosphates, carbamates, formamidines, macrocyclic lactones, amidinohydrazones, GABA antagonists and acetylcholine receptor ligands. Also provided are methods for synergistic insect control and crop protection.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 23, 2010
    Assignee: BASF Aktiengesellschaft
    Inventors: Michael Frank Treacy, Raymond Frank Borysewicz, Kurt Allen Schwinghammer, Paul E. Rensner, Hassan Oloumi-Sadeghi
  • Patent number: 7820656
    Abstract: Disclosed is a medicament comprising N-aryl N? morpholino/piperidino thiocarbamide derivatives represented by the following formula 1 for preventing and treating diabetes, diabetic complications, insulin resistance and insulin resistance syndrome, and can be used in drugs, foods, and beverages inducing an effect of preventing and treating diabetes, diabetic complications, insulin resistance and insulin resistance syndrome of modern people who suffer from the increasing development of diabetes resulting from environmental factors, such as intake of westernized foods, obesity, and so on: wherein, X is O or C, and R represents 4-chlorophenyl, 2-methylphenyl, 3-methoxypheny, 3-methylphenyl, or phenyl group.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: October 26, 2010
    Inventor: Sung-Jin Kim
  • Patent number: 7772281
    Abstract: The present invention provides a synergistic insecticidal composition comprising as essential active ingredients a neuronal sodium channel antagonist in combination with one or more compounds selected from the group consisting of pyrethroids, pyrethroid-type compounds, recombinant nucleopolyhedroviruses capable of expressing an insect toxin, organophosphates, carbamates, formamidines, macrocyclic lactones, amidinohydrazones, GABA antagonists and acetylcholine receptor ligands. Also provided are methods for synergistic insect control and crop protection.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: August 10, 2010
    Assignee: BASF Aktiengesellschaft
    Inventors: Michael Frank Treacy, Raymond Frank Borysewicz, Kurt Allen Schwinghammer, Paul E. Rensner, Hassan Oloumi-Sadeghi
  • Patent number: 7772282
    Abstract: The present invention provides a synergistic insecticidal composition comprising as essential active ingredients a neuronal sodium channel antagonist in combination with one or more compounds selected from the group consisting of pyrethroids, pyrethroid-type compounds, recombinant nucleopolyhedroviruses capable of expressing an insect toxin, organophosphates, carbamates, formamidines, macrocyclic lactones, amidinohydrazones, GABA antagonists and acetylcholine receptor ligands. Also provided are methods for synergistic insect control and crop protection.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: August 10, 2010
    Assignee: BASF Aktiengesellschaft
    Inventors: Michael Frank Treacy, Raymond Frank Borysewicz, Kurt Allen Schwinghammer, Paul E. Rensner, Hassan Oloumi-Sadeghi
  • Patent number: 7772283
    Abstract: The present invention provides a synergistic insecticidal composition comprising as essential active ingredients a neuronal sodium channel antagonist in combination with one or more compounds selected from the group consisting of pyrethroids, pyrethroid-type compounds, recombinant nucleopolyhedroviruses capable of expressing an insect toxin, organophosphates, carbamates, formamidines, macrocyclic lactones, amidinohydrazones, GABA antagonists and acetylcholine receptor ligands. Also provided are methods for synergistic insect control and crop protection.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: August 10, 2010
    Assignee: BASF Aktiengesellschaft
    Inventors: Michael Frank Treacy, Raymond Frank Borysewicz, Kurt Allen Schwinghammer, Paul E. Rensner, Hassan Oloumi-Sadeghi
  • Publication number: 20090324580
    Abstract: The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
    Type: Application
    Filed: March 9, 2007
    Publication date: December 31, 2009
    Applicants: CENIX BIOSCIENCE GMBH, INSTITUTO DE MEDICINA MOLECULAR , FACULDADE DE MEDICINA DA UNIVERSIDADA DE LISBOA
    Inventors: Michael Hannus, Cecilie Martin, Maria M. Mota, Miguel Prudencio, Christina Dias Rodrigues
  • Patent number: 6911460
    Abstract: The present invention relates to methods of treating viral or fungal infections using 3-aminopyridine-2-carboxyaldehyde thiosemicarbazone (3-AP) and 3-amino-4-methylpyridine-2-carboxaldehyde thiosemicarbazone (3-AMP) and its prodrug forms and to pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: June 28, 2005
    Assignees: Vion Pharmaceuticals, Inc., Yale University
    Inventors: Ivan C. King, Terrance W. Doyle, Mario Sznol, Alan C. Sartorelli, Yung-Chi Cheng
  • Publication number: 20040110730
    Abstract: Reagents and methods are provided for crosslinking and immobilizing biomolecules, drugs and synthetic polymers. The reagents possess (i) a thiol or amino reactive group; and (ii) a hydrazino or oxyamino moiety. Conjugates and immobilized biomolecules are also provided.
    Type: Application
    Filed: November 24, 2003
    Publication date: June 10, 2004
    Inventor: David A. Schwartz
  • Publication number: 20040058990
    Abstract: Invented are non-peptide TPO mimetics. also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted thiosemicarbazone derivative.
    Type: Application
    Filed: June 19, 2003
    Publication date: March 25, 2004
    Inventors: Kevin J. Duffy, Juan I Luengo, Stephen G. Miller, Julian Jenkins, Alan T. Price, Antony N. Shaw
  • Publication number: 20030114531
    Abstract: Halogenated derivatives of two synthetic anti-tuberculosis agents, thioacetazone and p-aminosalicylic acid, have been synthesized.
    Type: Application
    Filed: September 9, 2002
    Publication date: June 19, 2003
    Inventors: Farzad Kobarfard, Joel M. Kauffman
  • Publication number: 20020173548
    Abstract: Halogenated derivatives of two synthetic anti-tuberculosis agents, thioacetazone and p-aminosalicylic acid, have been synthesized.
    Type: Application
    Filed: March 9, 2001
    Publication date: November 21, 2002
    Inventors: Farzad Kobarfard, Joel M. Kauffman
  • Publication number: 20020061886
    Abstract: This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: 1
    Type: Application
    Filed: December 6, 2001
    Publication date: May 23, 2002
    Applicant: CoCensys, Inc.
    Inventors: Yan Wang, Sui Xiong Cai, John FW Keana
  • Patent number: 6323191
    Abstract: Cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride (Cl−) channel regulated by phosphorylation and intracellular nucleotides. CFTR is the major Cl− transport pathway in airway epithelial cells. The abnormal transepithelial Cl− transport and subsequent defective fluid transport caused by CF is a result of the genetic mutations of the gene coding for the CFTR protein. The present invention is directed to the novel use of ionophores as artificial Cl− transport pathways into CF epithelia to treat the defective Cl− and fluid transport lonophores and in particular, small molecule ionophores, represent a potential novel means of treating CF. The invention also includes using an ionophore to generate chloride secretion on intact monolayers of airway epithelia cells and other epithelia cells by administering an ionophore to a mammal.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: November 27, 2001
    Assignee: Genzyme Corporation
    Inventors: David J. Harris, Edward R. Lee, Canwen Jiang, Seng H. Cheng, Mathieu Lane
  • Patent number: 6316467
    Abstract: Compounds of this invention increase plasma levels of high density lipoprotein or HDL, the “good” cholesterol and as such may be useful for treating diseases such as atherosclerosis.
    Type: Grant
    Filed: November 16, 1998
    Date of Patent: November 13, 2001
    Assignee: American Home Products Corporation
    Inventor: Thomas J. Commons
  • Patent number: 6207715
    Abstract: Compounds of the formula: are useful in the treatment of diseases associated with herpes viruses including human cytomegalovirus, herpes simplex viruses, Epstein-Barr virus, varicella-zoster virus, human herpesviruses-6 and -7, and Kaposi herpes virus.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: March 27, 2001
    Assignee: American Home Products Corporation
    Inventors: Jonathan Bloom, Kevin Curran, Martin DiGrandi, Russell Dushin, Stanley Lang, Emily Norton, Adma Ross, Bryan O'Hara
  • Patent number: 5571843
    Abstract: Therapeutic compounds having the formula: ##STR1## in which R.sub.2 and R.sub.3 independently denote H, C.sub.1 -C.sub.4 alkoxy or OH and (A, B)=(oxygen, oxygen) in which case one out of R and R.sub.1 denotes OH, halogen, secondary amino or tertiary amine and the other denotes NHNHCONHR.sub.4 or R and R.sub.1 together denote .dbd.N--NH--CX--NHR.sub.5, .dbd.N--NH--CX--N(phenyl).sub.2, .dbd.N--NH--CX--NH--NH--R.sub.5, .dbd.N--NH--C(SCH.sub.3).dbd.N--R.sub.6 or .dbd.N--N.dbd.C(SCH.sub.3)--NH--R.sub.6 ; or (A, B)=(N--OH, oxygen) in which case R and R.sub.1 together form .dbd.N--NH--CX--NHR.sub.5 or .dbd.N--NH--CX--N(phenyl).sub.2 ; or (A, B)=(N--NH--CX--NHR.sub.5, oxygen) in which case R and R.sub.1 together form .dbd.N--NH--CX--NHR.sub.5 ; or (A, B)=(N--OH, N--OH) in which case R and R.sub.1 together form .dbd.N--NH--CX--NHR.sub.5 or .dbd.N--NH--CX--N(phenyl).sub.2.
    Type: Grant
    Filed: March 24, 1994
    Date of Patent: November 5, 1996
    Assignee: Innothera
    Inventors: Michel P. Cugnon de Sevricourt, Catherine G. Dacquet, Michel A. Finet, Florence J. Le Marquer, Max F. Robba, Norbert O. Tembo, Sylvie J. Yannic-Arnoult, Jean-Luc Torregrosa
  • Patent number: 5137877
    Abstract: The present invention provides novel N-substituted hydrazine bifunctional compounds, novel N-subhstituted hydrazone derivatives of a cytotoxic reagent incorporating the bifunctional compounds, novel conjugates containing at least one cytotoxic reagent molecule reacted with the bifunctional compound and bound to a molecule reactive with a target cell population, methods for their production, and pharmaceutical compositions and methods for delivering cytotoxic reagents to a target population of cells. The hydrazone bonds of the conjugates of the invention permit the release of free cytotoxic reagent from the conjugates in the acidic external or internal environment of the target cells. The bifunctional compounds, derivatives, conjugates and methods of the invention are useful in antibody-or ligand-mediated drug delivery systems for the perferential killing of a target cell population to treat diseases such as cancers, infections and autoimmune disorders.
    Type: Grant
    Filed: May 14, 1990
    Date of Patent: August 11, 1992
    Assignee: Bristol-Myers Squibb
    Inventors: Takushi Kaneko, David Willner, Ivo Monkovic, Robert S. Greenfield, Gary R. Braslawsky
  • Patent number: 5010104
    Abstract: Novel tricyclic compounds having a TXA.sub.2 -antagonizing activity represented by formul (I): ##STR1## which strongly antagonize an action of thromboxane A.sub.2 and are expected to have preventive and therapeutic effects on ischemica diseases, cerebro-vascular diseases, etc.
    Type: Grant
    Filed: June 29, 1989
    Date of Patent: April 23, 1991
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Etsuo Oshima, Hiroyuki Obase, Akira Karasawa, Kazuhiro Kubo, Ichiro Miki, Akio Ishii
  • Patent number: 4882339
    Abstract: Disclosed are compounds of the formula ##STR1## wherein R.sub.1 represents unsubstituted or lower alkyl-substituted C.sub.3 -C.sub.7 -cycloalkyl, unsubstituted or lower alkyl substituted C.sub.7 -or C.sub.8 -bicycloalkyl, unsubstituted or lower alkyl-substituted adamantyl, 4-piperidinyl or N-lower alkyl or aryl-lower alkyl-substituted piperidinyl, 1- or 2-indanyl, 1- or 2-tetrahydronaphthyl, 1- or 2-perhydroindanyl, 1- or 2-perhydronaphthyl; R.sub.2 represents hydrogen, lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, aryl-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, lower alkanoyl or aryl-lower alkanoyl; or R.sub.1 and R.sub.2 combined with the nitrogen to which they are attached represent pyrrolidino, piperidino, perhydroazepino, morpholino, thiomorpholino, tetrahydro- or perhydro-(isoquinolinyl or quinolinyl), dihydro- or perhydroindolyl, piperazino or N-lower alkyl-piperazino; R.sub.
    Type: Grant
    Filed: July 10, 1987
    Date of Patent: November 21, 1989
    Assignee: Ciba-Geigy Corporation
    Inventor: Jan W. F. Wasley
  • Patent number: 4514419
    Abstract: Hydrazinecarboxamides and carbothioamides of the formula ##STR1## wherein R.sub.1 is selected from alkyl, cyanoalkyl, hydroxyalkyl, and benzyl, R.sub.2 is hydrogen or alkyl, Y is oxygen or sulfur, n is 0-5, and Z is substituted for hydrogen and independently selected from halogen, alkyl, alkoxy, phenoxy, trifluoromethyl, and nitro are useful as nematicides when applied to or incorporated into nematode-infested soil.
    Type: Grant
    Filed: May 18, 1983
    Date of Patent: April 30, 1985
    Assignees: FMC Corporation, Kanagawa Chemical Laboratory, Ltd.
    Inventors: Philip A. Cruickshank, Carmine P. DiSanzo, Kiyosi Kondo, Hiromichi Kono